Our weekly market outlook, straight to your inbox.

Get the Schaeffer’s edge every Monday.

 

 
 
 
X

Buzz Stocks: FedEx, Anheuser Busch, Intra-Cellular Therapies

Sep 16, 2015, 10:09 AM by Mark Fightmaster
Today's stocks to watch include FedEx Corporation (FDX), Anheuser Busch Inbev SA (ADR) (BUD), and Intra-Cellular Therapies Inc (ITCI)
U.S. stocks are slightly higher this morning, remaining cautious as the Federal Open Market Committee (FOMC) begins its highly anticipated two-day meeting. In addition to the Fed, traders are digesting the consumer price index (CPI), which showed an unexpected drop in August. Today's equities in focus are package delivery firm FedEx Corporation (NYSE: FDX), beer baron Anheuser Busch Inbev SA (ADR) (NYSE:BUD), and biopharmaceutical concern Intra-Cellular Therapies Inc (NASDAQ:ITCI).

  1. FDX is 2.6% lower at $150.01, after cutting its fiscal-year outlook (subscription required). The freight firm blamed the move on weak demand in its freight segment and higher costs in its ground segment. FedEx Corporation slipped along with the broader equities market in August, but seems to have found a foothold atop its 32-week moving average. Meanwhile, 11 of the 18 brokerages tracking the delivery company rate it a "strong buy," leaving the stock vulnerable to potentail downgrades. As for options players, calls have recently outstripped puts in the option pits, suggesting traders were hoping for a post-earnings move higher.
  • BUD is 6.5% higher at $115.11, after news surfaced that the beverage behemoth has approached SABMiller about a takeover. It is believed the deal will value SABMiller "well in excess" of $75 billion while creating a brewing Goliath that will likely lord over the beverage market. Anheuser Busch Inbev SA (ADR) is now back in the black for 2015, and attempting to take out its 10-week moving average for the first time since late July. Option players are likely cheering the M&A buzz, as the stock's 10-day call/put volume ratio on the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) sits at 6.86 -- above 69% of all other readings from the past year.

  • ITCI jumped nearly 80% out of the gate -- and hit a record high of $46.68 -- after announcing that its experimental lead drug met its main goal of reducing the severity of schizophrenia symptoms. Intra-Cellular Therapies Inc could see a bit of a short-covering burst, too, as nearly 11% of its float is sold short. At ITCI's average pace of trading, it would take about a week to buy back all these bearish bets. At last check, ITCI was up 75% at $45.77.

Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!

Buzz Stocks: FedEx, Anheuser Busch, Intra-Cellular Therapies

by Mark Fightmaster | Sep 16, 2015
U.S. stocks are slightly higher this morning, remaining cautious as the Federal Open Market Committee (FOMC) begins its highly anticipated two-day meeting. In addition to the Fed, traders are digesting the consumer price index (CPI), which showed an unexpected drop in August. Today's equities in focus are package delivery firm FedEx Corporation (NYSE: FDX), beer baron Anheuser Busch Inbev SA (ADR) (NYSE:BUD), and biopharmaceutical concern Intra-Cellular Therapies Inc (NASDAQ:ITCI).

  1. FDX is 2.6% lower at $150.01, after cutting its fiscal-year outlook (subscription required). The freight firm blamed the move on weak demand in its freight segment and higher costs in its ground segment. FedEx Corporation slipped along with the broader equities market in August, but seems to have found a foothold atop its 32-week moving average. Meanwhile, 11 of the 18 brokerages tracking the delivery company rate it a "strong buy," leaving the stock vulnerable to potentail downgrades. As for options players, calls have recently outstripped puts in the option pits, suggesting traders were hoping for a post-earnings move higher.
  • BUD is 6.5% higher at $115.11, after news surfaced that the beverage behemoth has approached SABMiller about a takeover. It is believed the deal will value SABMiller "well in excess" of $75 billion while creating a brewing Goliath that will likely lord over the beverage market. Anheuser Busch Inbev SA (ADR) is now back in the black for 2015, and attempting to take out its 10-week moving average for the first time since late July. Option players are likely cheering the M&A buzz, as the stock's 10-day call/put volume ratio on the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) sits at 6.86 -- above 69% of all other readings from the past year.

  • ITCI jumped nearly 80% out of the gate -- and hit a record high of $46.68 -- after announcing that its experimental lead drug met its main goal of reducing the severity of schizophrenia symptoms. Intra-Cellular Therapies Inc could see a bit of a short-covering burst, too, as nearly 11% of its float is sold short. At ITCI's average pace of trading, it would take about a week to buy back all these bearish bets. At last check, ITCI was up 75% at $45.77.

Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!

Buzz Stocks: FedEx, Anheuser Busch, Intra-Cellular Therapies

by Mark Fightmaster | Sep 16, 2015
U.S. stocks are slightly higher this morning, remaining cautious as the Federal Open Market Committee (FOMC) begins its highly anticipated two-day meeting. In addition to the Fed, traders are digesting the consumer price index (CPI), which showed an unexpected drop in August. Today's equities in focus are package delivery firm FedEx Corporation (NYSE: FDX), beer baron Anheuser Busch Inbev SA (ADR) (NYSE:BUD), and biopharmaceutical concern Intra-Cellular Therapies Inc (NASDAQ:ITCI).

  1. FDX is 2.6% lower at $150.01, after cutting its fiscal-year outlook (subscription required). The freight firm blamed the move on weak demand in its freight segment and higher costs in its ground segment. FedEx Corporation slipped along with the broader equities market in August, but seems to have found a foothold atop its 32-week moving average. Meanwhile, 11 of the 18 brokerages tracking the delivery company rate it a "strong buy," leaving the stock vulnerable to potentail downgrades. As for options players, calls have recently outstripped puts in the option pits, suggesting traders were hoping for a post-earnings move higher.
  • BUD is 6.5% higher at $115.11, after news surfaced that the beverage behemoth has approached SABMiller about a takeover. It is believed the deal will value SABMiller "well in excess" of $75 billion while creating a brewing Goliath that will likely lord over the beverage market. Anheuser Busch Inbev SA (ADR) is now back in the black for 2015, and attempting to take out its 10-week moving average for the first time since late July. Option players are likely cheering the M&A buzz, as the stock's 10-day call/put volume ratio on the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) sits at 6.86 -- above 69% of all other readings from the past year.

  • ITCI jumped nearly 80% out of the gate -- and hit a record high of $46.68 -- after announcing that its experimental lead drug met its main goal of reducing the severity of schizophrenia symptoms. Intra-Cellular Therapies Inc could see a bit of a short-covering burst, too, as nearly 11% of its float is sold short. At ITCI's average pace of trading, it would take about a week to buy back all these bearish bets. At last check, ITCI was up 75% at $45.77.

Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!

  

ABOUTus


Schaeffer's Investment Research, Inc. has been providing stock market publications, market recommendation services and stock option education since its inception in 1981 by founder and CEO, Bernie Schaeffer.  Headquartered in Cincinnati, OH, Schaeffer's Investment Research has become a leading and trusted source of research and analysis for individual investors and major financial media outlets.

TRADINGpublications


|FROM THE TOP
by bernie schaeffer
Because today's investor is aware of the benefits of options trading, options investing is shifting to mainstream popularity, Bernie Schaeffer, author of The Option Advisor, continues to provide accessible, sophisticated analysis and research of options trading for every investor in his weekly and monthly columns.

Buzz Stocks: FedEx, Anheuser Busch, Intra-Cellular Therapies

by Mark Fightmaster | Sep 16, 2015
U.S. stocks are slightly higher this morning, remaining cautious as the Federal Open Market Committee (FOMC) begins its highly anticipated two-day meeting. In addition to the Fed, traders are digesting the consumer price index (CPI), which showed an unexpected drop in August. Today's equities in focus are package delivery firm FedEx Corporation (NYSE: FDX), beer baron Anheuser Busch Inbev SA (ADR) (NYSE:BUD), and biopharmaceutical concern Intra-Cellular Therapies Inc (NASDAQ:ITCI).

  1. FDX is 2.6% lower at $150.01, after cutting its fiscal-year outlook (subscription required). The freight firm blamed the move on weak demand in its freight segment and higher costs in its ground segment. FedEx Corporation slipped along with the broader equities market in August, but seems to have found a foothold atop its 32-week moving average. Meanwhile, 11 of the 18 brokerages tracking the delivery company rate it a "strong buy," leaving the stock vulnerable to potentail downgrades. As for options players, calls have recently outstripped puts in the option pits, suggesting traders were hoping for a post-earnings move higher.
  • BUD is 6.5% higher at $115.11, after news surfaced that the beverage behemoth has approached SABMiller about a takeover. It is believed the deal will value SABMiller "well in excess" of $75 billion while creating a brewing Goliath that will likely lord over the beverage market. Anheuser Busch Inbev SA (ADR) is now back in the black for 2015, and attempting to take out its 10-week moving average for the first time since late July. Option players are likely cheering the M&A buzz, as the stock's 10-day call/put volume ratio on the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) sits at 6.86 -- above 69% of all other readings from the past year.

  • ITCI jumped nearly 80% out of the gate -- and hit a record high of $46.68 -- after announcing that its experimental lead drug met its main goal of reducing the severity of schizophrenia symptoms. Intra-Cellular Therapies Inc could see a bit of a short-covering burst, too, as nearly 11% of its float is sold short. At ITCI's average pace of trading, it would take about a week to buy back all these bearish bets. At last check, ITCI was up 75% at $45.77.

Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!

From The Top

Buzz Stocks: FedEx, Anheuser Busch, Intra-Cellular Therapies

by Mark Fightmaster | Sep 16, 2015
U.S. stocks are slightly higher this morning, remaining cautious as the Federal Open Market Committee (FOMC) begins its highly anticipated two-day meeting. In addition to the Fed, traders are digesting the consumer price index (CPI), which showed an unexpected drop in August. Today's equities in focus are package delivery firm FedEx Corporation (NYSE: FDX), beer baron Anheuser Busch Inbev SA (ADR) (NYSE:BUD), and biopharmaceutical concern Intra-Cellular Therapies Inc (NASDAQ:ITCI).

  1. FDX is 2.6% lower at $150.01, after cutting its fiscal-year outlook (subscription required). The freight firm blamed the move on weak demand in its freight segment and higher costs in its ground segment. FedEx Corporation slipped along with the broader equities market in August, but seems to have found a foothold atop its 32-week moving average. Meanwhile, 11 of the 18 brokerages tracking the delivery company rate it a "strong buy," leaving the stock vulnerable to potentail downgrades. As for options players, calls have recently outstripped puts in the option pits, suggesting traders were hoping for a post-earnings move higher.
  • BUD is 6.5% higher at $115.11, after news surfaced that the beverage behemoth has approached SABMiller about a takeover. It is believed the deal will value SABMiller "well in excess" of $75 billion while creating a brewing Goliath that will likely lord over the beverage market. Anheuser Busch Inbev SA (ADR) is now back in the black for 2015, and attempting to take out its 10-week moving average for the first time since late July. Option players are likely cheering the M&A buzz, as the stock's 10-day call/put volume ratio on the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) sits at 6.86 -- above 69% of all other readings from the past year.

  • ITCI jumped nearly 80% out of the gate -- and hit a record high of $46.68 -- after announcing that its experimental lead drug met its main goal of reducing the severity of schizophrenia symptoms. Intra-Cellular Therapies Inc could see a bit of a short-covering burst, too, as nearly 11% of its float is sold short. At ITCI's average pace of trading, it would take about a week to buy back all these bearish bets. At last check, ITCI was up 75% at $45.77.

Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!

|MONDAY MORNING OUTLOOK
by todd salamone
Todd Salamone is the Senior VP of Research and author of the Monday Morning Outlook. To receive your weekly column, subscribe to Monday Morning Outlook.

Buzz Stocks: FedEx, Anheuser Busch, Intra-Cellular Therapies

by Mark Fightmaster | Sep 16, 2015
U.S. stocks are slightly higher this morning, remaining cautious as the Federal Open Market Committee (FOMC) begins its highly anticipated two-day meeting. In addition to the Fed, traders are digesting the consumer price index (CPI), which showed an unexpected drop in August. Today's equities in focus are package delivery firm FedEx Corporation (NYSE: FDX), beer baron Anheuser Busch Inbev SA (ADR) (NYSE:BUD), and biopharmaceutical concern Intra-Cellular Therapies Inc (NASDAQ:ITCI).

  1. FDX is 2.6% lower at $150.01, after cutting its fiscal-year outlook (subscription required). The freight firm blamed the move on weak demand in its freight segment and higher costs in its ground segment. FedEx Corporation slipped along with the broader equities market in August, but seems to have found a foothold atop its 32-week moving average. Meanwhile, 11 of the 18 brokerages tracking the delivery company rate it a "strong buy," leaving the stock vulnerable to potentail downgrades. As for options players, calls have recently outstripped puts in the option pits, suggesting traders were hoping for a post-earnings move higher.
  • BUD is 6.5% higher at $115.11, after news surfaced that the beverage behemoth has approached SABMiller about a takeover. It is believed the deal will value SABMiller "well in excess" of $75 billion while creating a brewing Goliath that will likely lord over the beverage market. Anheuser Busch Inbev SA (ADR) is now back in the black for 2015, and attempting to take out its 10-week moving average for the first time since late July. Option players are likely cheering the M&A buzz, as the stock's 10-day call/put volume ratio on the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) sits at 6.86 -- above 69% of all other readings from the past year.

  • ITCI jumped nearly 80% out of the gate -- and hit a record high of $46.68 -- after announcing that its experimental lead drug met its main goal of reducing the severity of schizophrenia symptoms. Intra-Cellular Therapies Inc could see a bit of a short-covering burst, too, as nearly 11% of its float is sold short. At ITCI's average pace of trading, it would take about a week to buy back all these bearish bets. At last check, ITCI was up 75% at $45.77.

Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!

|INDICATOR OF THE WEEK
by rocky white
Rocky White is a quantitative analyst at Schaeffer’s Research and author of Indicator of the Week. To get more tips on options indicators, subscribe to any of our free publications.

Buzz Stocks: FedEx, Anheuser Busch, Intra-Cellular Therapies

by Mark Fightmaster | Sep 16, 2015
U.S. stocks are slightly higher this morning, remaining cautious as the Federal Open Market Committee (FOMC) begins its highly anticipated two-day meeting. In addition to the Fed, traders are digesting the consumer price index (CPI), which showed an unexpected drop in August. Today's equities in focus are package delivery firm FedEx Corporation (NYSE: FDX), beer baron Anheuser Busch Inbev SA (ADR) (NYSE:BUD), and biopharmaceutical concern Intra-Cellular Therapies Inc (NASDAQ:ITCI).

  1. FDX is 2.6% lower at $150.01, after cutting its fiscal-year outlook (subscription required). The freight firm blamed the move on weak demand in its freight segment and higher costs in its ground segment. FedEx Corporation slipped along with the broader equities market in August, but seems to have found a foothold atop its 32-week moving average. Meanwhile, 11 of the 18 brokerages tracking the delivery company rate it a "strong buy," leaving the stock vulnerable to potentail downgrades. As for options players, calls have recently outstripped puts in the option pits, suggesting traders were hoping for a post-earnings move higher.
  • BUD is 6.5% higher at $115.11, after news surfaced that the beverage behemoth has approached SABMiller about a takeover. It is believed the deal will value SABMiller "well in excess" of $75 billion while creating a brewing Goliath that will likely lord over the beverage market. Anheuser Busch Inbev SA (ADR) is now back in the black for 2015, and attempting to take out its 10-week moving average for the first time since late July. Option players are likely cheering the M&A buzz, as the stock's 10-day call/put volume ratio on the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) sits at 6.86 -- above 69% of all other readings from the past year.

  • ITCI jumped nearly 80% out of the gate -- and hit a record high of $46.68 -- after announcing that its experimental lead drug met its main goal of reducing the severity of schizophrenia symptoms. Intra-Cellular Therapies Inc could see a bit of a short-covering burst, too, as nearly 11% of its float is sold short. At ITCI's average pace of trading, it would take about a week to buy back all these bearish bets. At last check, ITCI was up 75% at $45.77.

Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!

Weekly Publications

Buzz Stocks: FedEx, Anheuser Busch, Intra-Cellular Therapies

by Mark Fightmaster | Sep 16, 2015
U.S. stocks are slightly higher this morning, remaining cautious as the Federal Open Market Committee (FOMC) begins its highly anticipated two-day meeting. In addition to the Fed, traders are digesting the consumer price index (CPI), which showed an unexpected drop in August. Today's equities in focus are package delivery firm FedEx Corporation (NYSE: FDX), beer baron Anheuser Busch Inbev SA (ADR) (NYSE:BUD), and biopharmaceutical concern Intra-Cellular Therapies Inc (NASDAQ:ITCI).

  1. FDX is 2.6% lower at $150.01, after cutting its fiscal-year outlook (subscription required). The freight firm blamed the move on weak demand in its freight segment and higher costs in its ground segment. FedEx Corporation slipped along with the broader equities market in August, but seems to have found a foothold atop its 32-week moving average. Meanwhile, 11 of the 18 brokerages tracking the delivery company rate it a "strong buy," leaving the stock vulnerable to potentail downgrades. As for options players, calls have recently outstripped puts in the option pits, suggesting traders were hoping for a post-earnings move higher.
  • BUD is 6.5% higher at $115.11, after news surfaced that the beverage behemoth has approached SABMiller about a takeover. It is believed the deal will value SABMiller "well in excess" of $75 billion while creating a brewing Goliath that will likely lord over the beverage market. Anheuser Busch Inbev SA (ADR) is now back in the black for 2015, and attempting to take out its 10-week moving average for the first time since late July. Option players are likely cheering the M&A buzz, as the stock's 10-day call/put volume ratio on the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) sits at 6.86 -- above 69% of all other readings from the past year.

  • ITCI jumped nearly 80% out of the gate -- and hit a record high of $46.68 -- after announcing that its experimental lead drug met its main goal of reducing the severity of schizophrenia symptoms. Intra-Cellular Therapies Inc could see a bit of a short-covering burst, too, as nearly 11% of its float is sold short. At ITCI's average pace of trading, it would take about a week to buy back all these bearish bets. At last check, ITCI was up 75% at $45.77.

Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!

TRADING SERVICES | FEATUREDproducts


By E.W. from Kentucky
I have tried many different programs and services in the past with mix results. Stop your search here. Schaeffer's Investment Research is bottom line the most professional, experienced, and confidence building investment research firm. After trying an initial package I spoke with my account manager, Nathane Sharp, who helped me tailor my trading style to the right package. His professionalism and experienced approach matched me perfectly. The track record speaks for itself and the money back guarantee sells you. I have found my investment firm for the rest of my trading career.
Options trading made simple.
Schaeffer's Investment Research, Inc. is dedicated to providing subscribers advantages in options trading and investing.  Our independent market research services create profitable opportunities for investors at every level.
FREE NEWS & ALERTS

Get the best of Schaeffer's financial market news every morning directly to your inbox.

Find Out How

TRENDINGnews


Buzz Stocks: FedEx, Anheuser Busch, Intra-Cellular Therapies

by Mark Fightmaster | Sep 16, 2015
U.S. stocks are slightly higher this morning, remaining cautious as the Federal Open Market Committee (FOMC) begins its highly anticipated two-day meeting. In addition to the Fed, traders are digesting the consumer price index (CPI), which showed an unexpected drop in August. Today's equities in focus are package delivery firm FedEx Corporation (NYSE: FDX), beer baron Anheuser Busch Inbev SA (ADR) (NYSE:BUD), and biopharmaceutical concern Intra-Cellular Therapies Inc (NASDAQ:ITCI).

  1. FDX is 2.6% lower at $150.01, after cutting its fiscal-year outlook (subscription required). The freight firm blamed the move on weak demand in its freight segment and higher costs in its ground segment. FedEx Corporation slipped along with the broader equities market in August, but seems to have found a foothold atop its 32-week moving average. Meanwhile, 11 of the 18 brokerages tracking the delivery company rate it a "strong buy," leaving the stock vulnerable to potentail downgrades. As for options players, calls have recently outstripped puts in the option pits, suggesting traders were hoping for a post-earnings move higher.
  • BUD is 6.5% higher at $115.11, after news surfaced that the beverage behemoth has approached SABMiller about a takeover. It is believed the deal will value SABMiller "well in excess" of $75 billion while creating a brewing Goliath that will likely lord over the beverage market. Anheuser Busch Inbev SA (ADR) is now back in the black for 2015, and attempting to take out its 10-week moving average for the first time since late July. Option players are likely cheering the M&A buzz, as the stock's 10-day call/put volume ratio on the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) sits at 6.86 -- above 69% of all other readings from the past year.

  • ITCI jumped nearly 80% out of the gate -- and hit a record high of $46.68 -- after announcing that its experimental lead drug met its main goal of reducing the severity of schizophrenia symptoms. Intra-Cellular Therapies Inc could see a bit of a short-covering burst, too, as nearly 11% of its float is sold short. At ITCI's average pace of trading, it would take about a week to buy back all these bearish bets. At last check, ITCI was up 75% at $45.77.

Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!

OPTIONSnews


Buzz Stocks: FedEx, Anheuser Busch, Intra-Cellular Therapies

by Mark Fightmaster | Sep 16, 2015
U.S. stocks are slightly higher this morning, remaining cautious as the Federal Open Market Committee (FOMC) begins its highly anticipated two-day meeting. In addition to the Fed, traders are digesting the consumer price index (CPI), which showed an unexpected drop in August. Today's equities in focus are package delivery firm FedEx Corporation (NYSE: FDX), beer baron Anheuser Busch Inbev SA (ADR) (NYSE:BUD), and biopharmaceutical concern Intra-Cellular Therapies Inc (NASDAQ:ITCI).

  1. FDX is 2.6% lower at $150.01, after cutting its fiscal-year outlook (subscription required). The freight firm blamed the move on weak demand in its freight segment and higher costs in its ground segment. FedEx Corporation slipped along with the broader equities market in August, but seems to have found a foothold atop its 32-week moving average. Meanwhile, 11 of the 18 brokerages tracking the delivery company rate it a "strong buy," leaving the stock vulnerable to potentail downgrades. As for options players, calls have recently outstripped puts in the option pits, suggesting traders were hoping for a post-earnings move higher.
  • BUD is 6.5% higher at $115.11, after news surfaced that the beverage behemoth has approached SABMiller about a takeover. It is believed the deal will value SABMiller "well in excess" of $75 billion while creating a brewing Goliath that will likely lord over the beverage market. Anheuser Busch Inbev SA (ADR) is now back in the black for 2015, and attempting to take out its 10-week moving average for the first time since late July. Option players are likely cheering the M&A buzz, as the stock's 10-day call/put volume ratio on the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) sits at 6.86 -- above 69% of all other readings from the past year.

  • ITCI jumped nearly 80% out of the gate -- and hit a record high of $46.68 -- after announcing that its experimental lead drug met its main goal of reducing the severity of schizophrenia symptoms. Intra-Cellular Therapies Inc could see a bit of a short-covering burst, too, as nearly 11% of its float is sold short. At ITCI's average pace of trading, it would take about a week to buy back all these bearish bets. At last check, ITCI was up 75% at $45.77.

Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!

EDITOR'Spicks


Buzz Stocks: FedEx, Anheuser Busch, Intra-Cellular Therapies

by Mark Fightmaster | Sep 16, 2015
U.S. stocks are slightly higher this morning, remaining cautious as the Federal Open Market Committee (FOMC) begins its highly anticipated two-day meeting. In addition to the Fed, traders are digesting the consumer price index (CPI), which showed an unexpected drop in August. Today's equities in focus are package delivery firm FedEx Corporation (NYSE: FDX), beer baron Anheuser Busch Inbev SA (ADR) (NYSE:BUD), and biopharmaceutical concern Intra-Cellular Therapies Inc (NASDAQ:ITCI).

  1. FDX is 2.6% lower at $150.01, after cutting its fiscal-year outlook (subscription required). The freight firm blamed the move on weak demand in its freight segment and higher costs in its ground segment. FedEx Corporation slipped along with the broader equities market in August, but seems to have found a foothold atop its 32-week moving average. Meanwhile, 11 of the 18 brokerages tracking the delivery company rate it a "strong buy," leaving the stock vulnerable to potentail downgrades. As for options players, calls have recently outstripped puts in the option pits, suggesting traders were hoping for a post-earnings move higher.
  • BUD is 6.5% higher at $115.11, after news surfaced that the beverage behemoth has approached SABMiller about a takeover. It is believed the deal will value SABMiller "well in excess" of $75 billion while creating a brewing Goliath that will likely lord over the beverage market. Anheuser Busch Inbev SA (ADR) is now back in the black for 2015, and attempting to take out its 10-week moving average for the first time since late July. Option players are likely cheering the M&A buzz, as the stock's 10-day call/put volume ratio on the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) sits at 6.86 -- above 69% of all other readings from the past year.

  • ITCI jumped nearly 80% out of the gate -- and hit a record high of $46.68 -- after announcing that its experimental lead drug met its main goal of reducing the severity of schizophrenia symptoms. Intra-Cellular Therapies Inc could see a bit of a short-covering burst, too, as nearly 11% of its float is sold short. At ITCI's average pace of trading, it would take about a week to buy back all these bearish bets. At last check, ITCI was up 75% at $45.77.

Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!

ANALYSTupdates


Buzz Stocks: FedEx, Anheuser Busch, Intra-Cellular Therapies

by Mark Fightmaster | Sep 16, 2015
U.S. stocks are slightly higher this morning, remaining cautious as the Federal Open Market Committee (FOMC) begins its highly anticipated two-day meeting. In addition to the Fed, traders are digesting the consumer price index (CPI), which showed an unexpected drop in August. Today's equities in focus are package delivery firm FedEx Corporation (NYSE: FDX), beer baron Anheuser Busch Inbev SA (ADR) (NYSE:BUD), and biopharmaceutical concern Intra-Cellular Therapies Inc (NASDAQ:ITCI).

  1. FDX is 2.6% lower at $150.01, after cutting its fiscal-year outlook (subscription required). The freight firm blamed the move on weak demand in its freight segment and higher costs in its ground segment. FedEx Corporation slipped along with the broader equities market in August, but seems to have found a foothold atop its 32-week moving average. Meanwhile, 11 of the 18 brokerages tracking the delivery company rate it a "strong buy," leaving the stock vulnerable to potentail downgrades. As for options players, calls have recently outstripped puts in the option pits, suggesting traders were hoping for a post-earnings move higher.
  • BUD is 6.5% higher at $115.11, after news surfaced that the beverage behemoth has approached SABMiller about a takeover. It is believed the deal will value SABMiller "well in excess" of $75 billion while creating a brewing Goliath that will likely lord over the beverage market. Anheuser Busch Inbev SA (ADR) is now back in the black for 2015, and attempting to take out its 10-week moving average for the first time since late July. Option players are likely cheering the M&A buzz, as the stock's 10-day call/put volume ratio on the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) sits at 6.86 -- above 69% of all other readings from the past year.

  • ITCI jumped nearly 80% out of the gate -- and hit a record high of $46.68 -- after announcing that its experimental lead drug met its main goal of reducing the severity of schizophrenia symptoms. Intra-Cellular Therapies Inc could see a bit of a short-covering burst, too, as nearly 11% of its float is sold short. At ITCI's average pace of trading, it would take about a week to buy back all these bearish bets. At last check, ITCI was up 75% at $45.77.

Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!

Partnercenter


OURfans